Wednesday, August 27th, 2025
Stock Profile: QNRX
QNRX Logo

Quoin Pharmaceuticals, Ltd. (QNRX)

Market: NASD | Currency: USD

Address: 42127 Pleasant Forest Court

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based Show more




📈 Quoin Pharmaceuticals, Ltd. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2025 - $0.028571 - 2025-04-09 - Stock split
Total Amount for 2025: $0.028571
2023 - $0.083333 - 2023-07-18 - Stock split
Total Amount for 2023: $0.083333
2022 - $0.080000 - 2022-08-01 - Stock split
Total Amount for 2022: $0.080000
2021 - $0.250000 - 2021-09-24 - Stock split
Total Amount for 2021: $0.250000
2019 - $0.200000 - 2019-10-23 - Stock split
Total Amount for 2019: $0.200000


📅 Earnings & EPS History for Quoin Pharmaceuticals, Ltd.


DateReported EPS
2025-08-07-6.27
2025-05-13-6.5
2025-03-13-9.73
2024-11-08-16.51
2024-08-08-13.67
2024-05-09-38.62
2024-03-13-72.8
2023-11-09-68.25
2023-08-03-73.48
2023-05-09-144.1
2023-03-09-173.8
2022-11-10-395.26
2022-08-18-1360.8
2022-05-23-1050
2022-04-1422207.53
2021-12-20-7402.51




📰 Related News & Research


No related articles found for "quoin pharmaceuticals".